S&P 500   2,996.62 (-0.34%)
DOW   26,804.35 (-0.09%)
QQQ   191.94 (-0.75%)
AAPL   239.86 (-0.27%)
FB   182.63 (-3.76%)
MSFT   136.46 (-1.42%)
GOOGL   1,240.54 (-0.30%)
AMZN   1,763.32 (-1.25%)
CGC   21.06 (+3.49%)
NVDA   195.49 (-0.27%)
MU   44.69 (-1.17%)
BABA   169.47 (-2.34%)
GE   9.05 (+2.96%)
AMD   31.51 (-1.65%)
T   38.19 (-0.10%)
F   9.06 (+0.33%)
PRI   125.72 (+0.02%)
BAC   31.18 (+0.52%)
GILD   65.96 (+1.15%)
DIS   132.51 (+1.73%)
S&P 500   2,996.62 (-0.34%)
DOW   26,804.35 (-0.09%)
QQQ   191.94 (-0.75%)
AAPL   239.86 (-0.27%)
FB   182.63 (-3.76%)
MSFT   136.46 (-1.42%)
GOOGL   1,240.54 (-0.30%)
AMZN   1,763.32 (-1.25%)
CGC   21.06 (+3.49%)
NVDA   195.49 (-0.27%)
MU   44.69 (-1.17%)
BABA   169.47 (-2.34%)
GE   9.05 (+2.96%)
AMD   31.51 (-1.65%)
T   38.19 (-0.10%)
F   9.06 (+0.33%)
PRI   125.72 (+0.02%)
BAC   31.18 (+0.52%)
GILD   65.96 (+1.15%)
DIS   132.51 (+1.73%)
Log in

Mersana Therapeutics Stock Price, News & Analysis (NASDAQ:MRSN)

$1.83
+0.12 (+7.02 %)
(As of 10/22/2019 04:00 PM ET)
Today's Range
$1.69
Now: $1.83
$1.86
50-Day Range
$1.42
MA: $1.77
$2.46
52-Week Range
$1.40
Now: $1.83
$8.06
Volume174,995 shs
Average Volume408,525 shs
Market Capitalization$87.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.44
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRSN
CUSIPN/A
Phone617-498-0020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.59 million
Book Value$0.38 per share

Profitability

Net Income$-64,260,000.00

Miscellaneous

Employees86
Market Cap$87.49 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive MRSN News and Ratings via Email

Sign-up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.


Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics Inc (NASDAQ:MRSN) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.38) by $0.02. The company earned $0.20 million during the quarter, compared to the consensus estimate of $1.08 million. Mersana Therapeutics had a negative net margin of 77.78% and a negative return on equity of 51.13%. View Mersana Therapeutics' Earnings History.

When is Mersana Therapeutics' next earnings date?

Mersana Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Mersana Therapeutics.

What price target have analysts set for MRSN?

5 brokers have issued 1 year price targets for Mersana Therapeutics' shares. Their forecasts range from $12.00 to $14.00. On average, they expect Mersana Therapeutics' stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 606.5% from the stock's current price. View Analyst Price Targets for Mersana Therapeutics.

What is the consensus analysts' recommendation for Mersana Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mersana Therapeutics.

Has Mersana Therapeutics been receiving favorable news coverage?

News coverage about MRSN stock has been trending extremely negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mersana Therapeutics earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Mersana Therapeutics.

Are investors shorting Mersana Therapeutics?

Mersana Therapeutics saw a drop in short interest in September. As of September 30th, there was short interest totalling 632,700 shares, a drop of 9.3% from the August 30th total of 697,900 shares. Based on an average trading volume of 239,800 shares, the days-to-cover ratio is currently 2.6 days. Approximately 1.8% of the company's stock are short sold. View Mersana Therapeutics' Current Options Chain.

Who are some of Mersana Therapeutics' key competitors?

What other stocks do shareholders of Mersana Therapeutics own?

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the folowing people:
  • Ms. Anna Protopapas, Pres, CEO & Director (Age 55)
  • Mr. David A. Spellman, Chief Financial Officer (Age 42)
  • Dr. Timothy B. Lowinger, Sr. VP & Chief Scientific Officer (Age 55)
  • Mr. Mikhail Papisov Ph.D., Co-Founder
  • Ms. Sarah Carmody, Exec. Director of Investor Relations & Corp. Communications

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (25.02%). Company insiders that own Mersana Therapeutics stock include Enterprise Associates 14 New and Timothy B Lowinger. View Institutional Ownership Trends for Mersana Therapeutics.

Which major investors are buying Mersana Therapeutics stock?

MRSN stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC. View Insider Buying and Selling for Mersana Therapeutics.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $1.84.

How big of a company is Mersana Therapeutics?

Mersana Therapeutics has a market capitalization of $87.97 million and generates $10.59 million in revenue each year. The company earns $-64,260,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe.View Additional Information About Mersana Therapeutics.

What is Mersana Therapeutics' official website?

The official website for Mersana Therapeutics is http://www.mersana.com/.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]


MarketBeat Community Rating for Mersana Therapeutics (NASDAQ MRSN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  320
MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote "Outperform" if you believe MRSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Featured Article: What is Green Investing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel